Provider Gaps in Postpartum Depression Screening and Management Highlighted in New Study
ACOG 2025: Laxmi Gannu, MS, discusses key findings from a provider survey on postpartum depression screening practices, training gaps, and referral patterns.
Despite widespread awareness of postpartum depression (PPD) screening guidelines, significant gaps persist in clinical practice, according to research presented at ACOG 2025 by Laxmi Gannu, MS, senior manager, real world evidence, at Sage Therapeutics. In this interview, Gannu reviews results from a national provider survey assessing adherence to screening protocols, follow-up care, and provider training. The findings reveal inconsistencies in protocol implementation, surprising misconceptions among physicians, and distinct differences in practice patterns between provider types. Gannu emphasized the need for ongoing education to improve screening and management of PPD, ensuring that all postpartum patients receive appropriate and timely care.
For other highlights and exclusive expert interviews, check out our full meeting coverage of the 2025 ACOG ACSM here.
Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD
June 11th 2025RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.
